MURTAZA EMRE DURAKOĞLUGİL
(Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Rize, Türkiye)
Teslime AYAZ
(Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Dahiliye Ana Bilim Dalı, Rize, Türkiye)
Sinan Altan KOCAMAN
(Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Rize, Türkiye)
Aynur KIRBAŞ
(Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Biyokimya Ana Bilim Dalı, Rize, Türkiye)
Tuğba DURAKOĞLUGİL
(Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Radyoloji Anabilim, Rize, Türkiye)
TURAN ERDOĞAN
(Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Rize, Türkiye)
MUSTAFA ÇETİN
(Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Rize, Türkiye)
Osman Zikrullah ŞAHİN
(Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Dahiliye Ana Bilim Dalı, Rize, Türkiye)
YÜKSEL ÇİÇEK
(Recep Tayyip Erdoğan Üniversitesi, Kardiyoloji Anabilim Dalı, Rize, Türkiye)
Yıl: 2015Cilt: 15Sayı: 7ISSN: 2149-2263 / 2149-2271Sayfa Aralığı: 577 - 585İngilizce

87 0
The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol
Fen > Tıp > Kalp ve Kalp Damar Sistemi
DergiAraştırma MakalesiErişime Açık
  • 1. Helle KB. The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc Res 2010; 85: 9-16. [CrossRef]
  • 2. Mahata SK, Mahata M, Fung MM, O’Connor DT. Catestatin: a mul- tifunctional peptide from chromogranin A. Regul Pept 2010; 162: 33-43. [CrossRef]
  • 3. Mahata SK, O’Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997; 100: 1623-33. [CrossRef]
  • 4. Mahata SK, Mahata M, Parmer RJ, O’Connor DT. Desensitization of catecholamine release. The novel catecholamine release-inhibito- ry peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem 1999; 274: 2920-8. [CrossRef]
  • 5. Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, et al. Catecholamine release-inhibitory peptide catestatin (chromo- granin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 2007; 115: 2271-81. [CrossRef]
  • 6. Mahata SK, Mahata M, Wen G, Wong WB, Mahapatra NR, Hamilton BA, et al. The catecholamine release-inhibitory “cates- tatin” fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nico- tinic cholinergic responses. Mol Pharmacol 2004; 66: 1180-91. [CrossRef]
  • 7. O’Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 2002; 20: 1335-45. [CrossRef]
  • 8. Delles C, Padmanabhan S. Genetics and hypertension: is it time to change my practice? Can J Cardiol 2012; 28: 296-304. [CrossRef]
  • 9. Cheung BM, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep 2012; 14: 160-6. [CrossRef]
  • 10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52. [CrossRef]
  • 11. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-8. [CrossRef]
  • 12. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65. [CrossRef]
  • 13. Kruger PG, Mahata SK, Helle KB. Catestatin (CgA344-364) stimu- lates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides. Regul Pept 2003; 114: 29-35. [CrossRef]
  • 14. Mineo C, Shaul PW. Novel biological functions of high-density lipoprotein cholesterol. Circ Res 2012; 111: 1079-90. [CrossRef]
  • 15. Bandyopadhyay GK, Vu CU, Gentile S, Lee H, Biswas N, Chi NW, et al. Catestatin (chromogranin A(352-372)) and novel effects on mobi- lization of fat from adipose tissue through regulation of adrenergic and leptin signaling. J Biol Chem 2012; 287: 23141-51. [CrossRef]
  • 16. Verghese PB, Arrese EL, Soulages JL. Stimulation of lipolysis enhances the rate of cholesterol efflux to HDL in adipocytes. Mol Cell Biochem 2007; 302: 241-8. [CrossRef]
  • 17. Zhang Y, McGillicuddy FC, Hinkle CC, O’Neill S, Glick JM, Rothblat GH, et al. Adipocyte modulation of high-density lipoprotein choles- terol. Circulation 2010; 121: 1347-55. [CrossRef]
  • 18. Mahapatra NR, O’Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005; 115: 1942-52. [CrossRef]
  • 19. Gayen JR, Gu Y, O’Connor DT, Mahata SK. Global disturbances in autonomic function yield cardiovascular instability and hyperten- sion in the chromogranin a null mouse. Endocrinology 2009; 150: 5027-35. [CrossRef]
  • 20. Kennedy BP, Mahata SK, O’Connor DT, Ziegler MG. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 1998; 19: 1241-8. [CrossRef]
  • 21. Fung MM, Salem RM, Mehtani P, Thomas B, Lu CF, Perez B, et al. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens 2010; 32: 278-87. [CrossRef]
  • 22. Papakonstantinou NA, Stamou MI, Baikoussis NG, Goudevenos J, Apostolakis E. Sex differentiation with regard to coronary artery disease. J Cardiol 2013; 62: 4-11. [CrossRef]
  • 23. Meng L, Ye XJ, Ding WH, Yang Y, Di BB, Liu L, et al. Plasma cate- cholamine release-inhibitory peptide catestatin in patients with essential hypertension. J Cardiovasc Med (Hagerstown) 2011; 12: 643-7. [CrossRef]
  • 24. Schillaci G, De Vuono S, Pucci G. An endogenous brake on the sympathetic nervous system: the emerging role of catestatin in hypertension. J Cardiovasc Med 2011; 12: 609-12. [CrossRef]
  • 25. Gamboa A, Okamoto LE, Diedrich A, Choi L, Robertson D, Farley G, et al. Sympathetic activation and nitric oxide function in early hypertension. Am J Physiol Heart Circ Physiol 2012; 302: H1438-43. [CrossRef]
  • 26. Seals DR, Esler MD. Human ageing and the sympathoadrenal system. J Physiol 2000; 528: 407-17. [CrossRef]

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.